[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
July 5, 2000

Joint Meeting of Advisory Committees

Author Affiliations

Not Available

Not Available

JAMA. 2000;284(1):33. doi:10.1001/jama.284.1.33-JFD00005-3-1

The FDA's Nonprescription Drugs and Endocrinologic and Metabolic Drugs committees will hold a joint meeting to consider applications for over-the-counter use of cholesterol-lowering agents. On July 13, the subject will be Mevacor (lovastatin, 10-mg tablets), and on July 14, Pravachol (pravastatin sodium, 10-mg tablets). The meeting will be at the Holiday Inn, 8120 Wisconsin Ave, Bethesda, Md. Interested persons may make oral presentations from 8 AM to 9 AM on July 13. Written submissions may be made to Sandra Titus or Kathleen Reedy, HFD-21, FDA, 5600 Fishers Lane, Rockville, MD 20857.

First Page Preview View Large
First page PDF preview
First page PDF preview